EXPLORER-HCM Trial finds substantial health status improvements with mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
Share Article
Saint Luke s Mid America Heart Institute shared trial findings at American College of Cardiology’s 2021 Scientific Session
The benefits observed were amongst the largest we have ever seen from a medication to improve the symptoms, function and quality of life of patients with heart failure. KANSAS CITY, Mo. (PRWEB) May 20, 2021 The EXPLORER-HCM (Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) Randomized Clinical Trial has shown significant improvement in the symptoms, function, and quality of life in patients with obstructive hypertrophic cardiomyopathy (oHCM) with taking mavecamten. This comes following no major advances for treating oHCM in more than 30 years, where the primary goals of treat
Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients
Phase III DARE-19 trial shows SGLT2 inhibitor is well-tolerated in acutely ill patients
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21.
May 18, 2021 Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 (SARS-CoV-2) who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology (ACC) 2021 Scientific Session.
May 17, 2021
Use of apixaban (Eliquis; Bristol-Myers Squibb) following transcatheter aortic valve implantation does not significantly reduce the risk of subclinical valve thrombosis when compared with standard of care, according to a CT substudy from the ATLANTIS trial presented today.
However, the results are nuanced, with investigators reporting an intriguing interaction between thrombus risk and prior oral anticoagulation indication. For patients without an indication for oral anticoagulation, use of apixaban as opposed to antiplatelet therapy was associated with a lower risk of subclinical valve thrombosis as measured by reduced leaflet motion (RLM) and hypoattenuated leaflet thickening (HALT).
By contrast, for those with an indication for oral anticoagulation, apixaban failed to prevent subclinical valve thrombosis when compared with a vitamin K antagonist.